[Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].

Abstract

CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes. Of the 11 eligible patients enrolled in the phase I study in Japan, 2 showed CR and 5 showed PR. 90 relapsed pts were enrolled in the subsequent phase II study and treated with rituximab at 375 mg/m2 x 4 weekly infusions. The overall response rates in relapsed indolent B-cell lymphoma and mantle cell lymphoma were 61%(37/61) and 46%(6/13), respectively. Rituximab is a novel, effective anti-lymphoma agent with acceptable toxicities.

• Authors: Kensei Tobinai
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 60 Issue 3 Pg. 468-72 (Mar 2002) ISSN: 0047-1852 [Print] Japan
• PMID: 11904960 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Antineoplastic Agents
• Recombinant Fusion Proteins
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20 (immunology)
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Humans
• Japan
• Lymphoma, B-Cell (drug therapy)
• Mice
• Prednisone (administration & dosage)
• Radioimmunotherapy
• Recombinant Fusion Proteins
• Rituximab
• Treatment Outcome
• United States
• Vincristine (administration & dosage)